Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

Koshy George is a true Medicine Man. He knew as a young boy growing up in India that he wanted to make medicine. With his parents encouragement, he earned both a Bachelor and Master degree in Pharmacy ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based 'Newco,' explain experts at Orrick.

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Chris Anzalone It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance ...